OTC

FDA labeling study helps clear path for OTC naloxone
FDA labeling study helps clear path for OTC naloxone
RAPS.org
Naloxone
FDA
OTC
Flag link:
Takeda to sell European OTC business to cut debts
Takeda to sell European OTC business to cut debts
Pharmaforum
Takeda
Europe
debt
OTC
Flag link:
Coronavirus Relief Bill Includes OTC Drug User Fee Program
Coronavirus Relief Bill Includes OTC Drug User Fee Program
RAPS.org
COVID-19
OTC
user fees
drug shortages
legislation
regulatory
Flag link:
FDA approves GSK’s Advil Dual Action with Acetaminophen OTC pain reliever
FDA approves GSK’s Advil Dual Action with Acetaminophen OTC pain reliever
Pharmaceutical Business Review
GSK
FDA
OTC
Advil Dual Action with Acetaminophen
Flag link:
Stada Buys 15 Over-the-Counter Products from GSK for $325 Million
Stada Buys 15 Over-the-Counter Products from GSK for $325 Million
BioSpace
GSK
consumer health
OTC
Stada
Flag link:
FDA approves GSK’s Voltaren Arthritis Pain for over-the-counter use in the US
FDA approves GSK’s Voltaren Arthritis Pain for over-the-counter use in the US
Pharmaceutical Business Review
GSK
Voltaren
arthritis
NSAID
OTC
FDA
Flag link:
What has Zantac recall cost drugmakers? Dr. Reddy's gives a hint
What has Zantac recall cost drugmakers? Dr. Reddy's gives a hint
Fierce Pharma
Zantac
OTC
product recalls
generics
Dr Reddy's
Flag link:
Zantac maker Sanofi joins peers in recalling antacid
Zantac maker Sanofi joins peers in recalling antacid
Fierce Pharma
Sanofi
OTC
product recalls
Zantac
FDA
Flag link:
GSK joins other drugmakers recalling Zantac products
GSK joins other drugmakers recalling Zantac products
Fierce Pharma
GSK
ranitidine
product recalls
OTC
Flag link:
GlaxoSmithKline halts generic Zantac supply as global threat gains steam
GlaxoSmithKline halts generic Zantac supply as global threat gains steam
Fierce Pharma
Novartis
GSK
generics
OTC
Zantac
product recalls
Flag link:
GSK's oral nicotine spray wins divided FDA panel's backing despite abuse risks
GSK's oral nicotine spray wins divided FDA panel's backing despite abuse risks
Fierce Pharma
GSK
FDA
advisory panels
OTC
Flag link:
Zantac and some OTC meds found to contain suspected carcinogen first discovered in blood pressure drugs
Zantac and some OTC meds found to contain suspected carcinogen first discovered in blood pressure drugs
Fierce Pharma
FDA
Zantac
Sanofi
OTC
cancer
Flag link:
GSK split edges closer as OTC joint venture deal with Pfizer closes
GSK split edges closer as OTC joint venture deal with Pfizer closes
Pharmaforum
GSK
Pfizer
OTC
M&A
Flag link:
Roche cuts loose Tamiflu OTC rights, handing Sanofi the keys as the pharma giant doubles down on Xofluza
Roche cuts loose Tamiflu OTC rights, handing Sanofi the keys as the pharma giant doubles down on Xofluza
Endpoints
Roche
Tamiflu
OTC
Xofluza
Sanofi
Flag link:
Daiichi Sankyo Denies Report That It's Selling Over-the-Counter Drug Unit
Daiichi Sankyo Denies Report That It's Selling Over-the-Counter Drug Unit
BioSpace
Daiichi Sankyo
OTC
Flag link:
Daiichi Sankyo in talks over OTC unit sale – reports
Daiichi Sankyo in talks over OTC unit sale – reports
Pharmaforum
Daiichi Sankyo
M&A
OTC
Flag link:
Taisho Nears $1.6 Billion Deal for Bristol-Myers Unit
Taisho Nears $1.6 Billion Deal for Bristol-Myers Unit
Bloomberg
Taisho
Bristol-Myers Squibb
OTC
Upsa
M&A
Flag link:
Crown Laboratories buys select OTC consumer healthcare brands from GSK
Crown Laboratories buys select OTC consumer healthcare brands from GSK
Pharmaceutical Business Review
Crown Laboratories
GSK
OTC
M&A
Flag link:
Takeda considering sale of OTC business in Europe ($11bn)
Takeda considering sale of OTC business in Europe ($11bn)
Bloomberg
Takeda
Shire
M&A
OTC
Flag link:
Stada and Mylan targeting Bristol-Myers Squibb’s Upsa (€1bn)
Stada and Mylan targeting Bristol-Myers Squibb’s Upsa (€1bn)
GoinPharma
Stada
OTC
Upsa
Bristol-Myers Squibb
Flag link:

Pages